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Cladosporols, puriﬁed and characterized as secondary metabolites from Cladosporium tenuissimum, display an anti-
fungal activity. In this study, we tested the antiproliferative properties of cladosporol A, the main isoform of this
metabolite family, against human cancer cell lines. By assessing cell viability, we found that cladosporol A inhibits the
growth of various human colon cancers derived cell lines (HT-29, SW480, and CaCo-2) in a time- and concentration-
dependent manner, speciﬁcally of HT-29 cells. The reduced cell proliferation was due to a G1-phase arrest, as assessed
by ﬂuorescence activated cell sorting analysis on synchronized HT-29 cells, and was associated with an early and
robust over-expression of p21waf1/cip1, the well-known cyclin-dependent kinases inhibitor. This suggests that the drug
may play a role in the control of cancer cell proliferation. Consistently, cyclin D1, cyclin E, CDK2, and CDK4 proteins
were reduced and histone H1-associated CDK2 kinase activity inhibited. In addition to p21waf1/cip1, exposure to
20 mM cladosporol A caused a simultaneous increase of pERK and pJNK, suggesting that this drug activates a circuit
that integrates cell cycle regulation and the signaling pathways both involved in the inhibition of cell proliferation.
Finally, we showed that the increase of p21waf1/cip1 expression was generated by a Sp1-dependent p53-independent
stimulation of its gene transcription as mutagenesis of the Sp1 binding sites located in the p21 proximal promoter
abolished induction. To our knowledge, this is the ﬁrst report showing that cladosporol A inhibits colon cancer cell
proliferation by modulating p21waf1/cip1 expression.  2011 Wiley Periodicals, Inc.
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INTRODUCTION
Chemoprevention consists in the administration
of natural and/or synthetic compounds to prevent
the occurrence of degenerative diseases and, more
recently, various cancer types. Vitamins, minerals,
carotenoids, ﬂavonoids, organsulfurs, isothiocya-
nates, indoles, monoterpenes, phenolic acids, and
chlorophylls, are all included in the list of natural
and already available compounds able to interfere
with the various steps of the carcinogenetic process
through different mechanisms and distinctive mole-
cules [1–3]. Isolation and characterization of new
natural molecules from plants, fungi, and micro-
rganisms will increase the number of these thera-
peutic tools to inhibit cancer cells proliferation.
Cladosporols are secondary metabolites puriﬁed
from Cladosporium tenuissimum, strain ITT21,
cultured in sugar-rich media [4]. This fungus is a
hyperparasite of rust fungi and its derived com-
pounds possess antifungal activity [5]. The main
metabolite was isolated as a white powder, repre-
senting more than 30% of the crude extract
(Figure 1A). Its spectral analyses were consistent
with a C20H16O6 molecular formula and a dimeric
decaketide binaphthyl structure [6]. Cladosporols
were initially characterized as plant regulators,
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then as inducers of hyphal malformations in Phyto-
phothora capsici and, lastly, as inhibitors of b-1, 3-
glucan synthetase, the enzyme responsible for the
synthesis of the fungal cell wall components [7,8].
Cladosporols are able to inhibit almost completely
spore germination in a great number of rust
fungi, such as Uromyces appendiculatus, Melampsora
pinitorqua, Cronartium ﬂaccidum, and provoke
the reduction of radial growth of non-rust fungi
as in colonies of the phytopathogenic fungi like
Alternaria alternata, Botrytis cinerea, Cercospora beti-
cola, among the Oomycota, Phytophthora capsici,
P. cinnamomi, P. erytroseptica and among human
pathogenic strains of Candida sp. The antifungal
activity of cladosporols likely resides in the intrin-
sic toxicity of the 2-tetralone chromophore and
in highly reactive functionalities, such as the ep-
oxy-alcohol moiety, very similar to (þ)-isoepoxi-
don, also reported as a b-1, 3-glucan biosynthesis
inhibitor, or other similar compounds [9–11].
These bioactive molecules strongly inﬂuence the
pathogenicity of C. tenuissimum and play a major
role in its hyperparasitism.
Colorectal cancer (CRC) is one of the most wide-
spread tumors in Western countries. The most re-
cent statistics conﬁrm that only in the USA about
146,970 new cases of CRCs will be diagnosed in
the next year and 49,920 patients will die of this
disease [12]. In addition to genetic alterations in
tumor suppressor genes, such as P53 and adenoma-
tous polyposis coli (APC), loss of cell cycle control,
increased cell survival signaling and inhibition of
apoptosis are the most common events observed
in CRC promotion and/or progression [13–15].
For these reasons, new molecules affecting
the cell cycle might be helpful tools to prevent the
earliest events in carcinogenesis [16,17]. Cell cycle
progression is modulated by cyclins and cyclin-
dependent kinases (CDKs) interactions [18]. These
protein complexes are sequentially activated dur-
ing the cell cycle allowing the transition through
the G1, S, and G2/M phases [19]. Under different
conditions, the cyclin-CDK complexes are inhib-
ited by the binding of CDK inhibitors (CDKIs),
two main groups of which have been identiﬁed
and characterized so far, the CIP/KIP and INK4
families [20,21]. p21waf1/cip1 is one of the most im-
portant members of the CIP/KIP family, is recog-
nized as a fundamental player in the control
of cell proliferation [22,23] and identiﬁed as the
target of the p53-dependent growth-arrest after
DNA-damage induction in various cell types
[24,25]. Indeed, p21waf1/cip1 expression is modulat-
ed through p53-dependent and -independent
mechanisms [26,27]. The majority of human can-
cers bear mutated forms of p53 and, therefore, it is
interesting to investigate p53-independent but
p21-mediated mechanisms of cell cycle regulation.
Novel ﬁndings on this topic might suggest new po-
tential intervention in managing human cancers.
Epidemiologic studies demonstrated a tight cor-
relation between CRC diffusion and red meat, fatty
acids, and alcohol intake [28]. Moreover, a dramat-
ic difference in CRC incidence has been observed
among populations of different ethnic groups that
may be ascribable to the different dietary regimens
followed in the different countries [29]. Thus, CRC
frequency in Europe and USA (where the con-
sumption of fat and red meat in the diet is very
high) is higher than that observed in Asia (where
people are used to eating large amounts of vegeta-
bles). Consumption of high amounts of fruit and
vegetables may result in a reduction of CRC occur-
rence and, therefore, a chemopreventive approach
could be a productive strategy to control the dis-
ease diffusion [30–32].
Along this reasoning, Chen et al. [33] have re-
cently demonstrated that the growth of the hu-
man gastric carcinoma derived cells (MGC-803)
is inhibited by cladosporol isolated from the
paclitaxel-producing strain Alternaria alternata var:
monosporus. Here, we tested the antiproliferative
properties of cladosporol A on three CRC derived
cell lines (HT-29, SW480, and CaCo-2) to elucidate
the underlying molecular mechanisms. In particu-
lar, we show that exposure of HT-29 cells to the
drug causes a p21-dependent, p53-independent
Figure 1. (A) Chemical structure of cladosporol A. (B) Dose-
dependent cytotoxicity of cladosporol A on HT-29 cells, as deter-
mined by the CellTiter Aqueous One Cell Proliferation Assay. Cells
were seeded in 96-well plates in order to reach the density
of 106 cells/cm2 in standard conditions (10% charcoal/dextran-
treated FBS containing 1% penicillin–streptomycin and 1% L-gluta-
mine). After 24 h, increasing concentrations of cladosporol A
(from 0.4 to 75 mM) were used to stimulate cells and the growth
was evaluated up to 72 h through measurement of absorbance at
490 nm. Results were expressed as the optical density ratio of the
difference between the control and the treated cells to the control
cells. Each point was done in triplicate and the experiment was
repeated two times.
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cell cycle arrest at the G1/S phase. This effect
is accompanied by a robust p21waf1/cip1 over-
expression, a signiﬁcant CDK2, CDK4, cyclin D1,
and cyclin E protein down-regulation and a CDK2
kinase activity inhibition. Moreover, we provide
the ﬁrst evidence that extracellular signal-regulated
protein kinase (ERK) [and c-Jun NH2-terminal
kinase (JNK) also] might function as mediator
of the cladosporol A-induced redox response
and inhibition of HT-29 cell growth. Finally,
our ﬁndings demonstrate that cladosporol A-
mediated impairment of CRC cell survival is due
to an Sp1-modulated increase of p21waf1/cip1 gene
transcription.
MATERIALS AND METHODS
Cells, Antibodies, and Reagents
HT-29, SW480, CaCo-2, and HCT116 (from hu-
man colon cancers) cells were obtained from the
American Type Culture Collection (Rockville, MD).
These cell lines bear different genetic abnormalities
typical of human CRC, because they have truncat-
ed or mutant APC gene. Moreover, SW480 cells ex-
press both P53 (Arg273 > His and Pro309 > Ser)
and RAS (Val12 > Glu) mutated forms. HT-29 cells
bear a mutated p53 (Arg 273 > His), but a wild-
type ras allele. HCT116 cells carry a mutated form
of RAS and a wild-type P53. HCT116 p53/ were
a kind gift from Dr. Bevilacqua (University of
Naples ‘‘Federico II’’). Finally, CaCo-2 cells express
wild-type RAS, but carry a mutated p53 allele form
[34].
Antibodies against p21waf1/cip1, cyclin E, D1, A
and B1, CDK2, CDK4, Cdc2p34, proliferating cell
nuclear antigen (PCNA), pERK, pJNK, p53, retino-
blastoma (RB), and b-actin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
mouse and anti-rabbit IgG peroxidase-linked sec-
ondary antibodies, A/G plus agarose beads, ECL
and ECL Plus Western blotting detection kit were
purchased from Amersham Life Science (Little
Chalfont, England). Dulbecco’s Modiﬁed Eagle’s
Medium (D-MEM), RPMI1640, D-luciferin sodium
salt, trichloroacetic acid, propidium iodide (PI),
thiazolinedione, apocynin, UO126 and PD98059
were from Sigma (St.Louis, MO). Fetal bovine se-
rum (FBS), penicillin–streptomycin, L-glutamine,
trypsin-EDTA, and OptiMEM I were obtained from
Gibco (Carlsbad, CA). Charcoal/dextran-treated
FBS was purchased from Hyclone (Logan, Utah).
Fetal calf serum, Lipofectamine 2000, TRIZOL, Su-
perScript II reverse transcriptase were from Invitro-
gen (Carlsbad, CA). The CellTiter Aqueous One
Cell Proliferation Assay was obtained from Prom-
ega (Madison, WI). SYBR Green and Ready Strip
IPG strips were purchased from BioRad (Hercules,
CA). AmpliTaq Gold was purchased from Applied
Biosystems (Foster City, CA).
Cell Culture and Cladosporol A Treatment
Human colon adenocarcinoma cell lines HT-29,
Caco-2, and SW480 were grown as a monolayer
in D-MEM containing 10% FBS, 1% penicillin–
streptomycin, and 1% L-glutamine. HCT116 were
grown in RPMI1640 medium containing 10% FBS,
1% penicillin–streptomycin and 1% L-glutamine.
All the cells were cultured in 100 mm plates, at
70–80% conﬂuence, in a 5% CO2 humidiﬁed
atmosphere, at 378C.
Cladosporol A treatments were carried out in
presence of 10% charcoal/dextran-treated FBS
containing 1% penicillin–streptomycin and 1%
L-glutamine, whereas the cells were maintained
at 40% conﬂuence. Cladosporol A was dissolved
in dimethylsulfoxide (DMSO) and mixed with
fresh medium to achieve the ﬁnal concentration.
In all treatments, the DMSO ﬁnal concentration
in the medium was <0.1%. In separate experi-
ments, cells were treated with increasing concen-
trations of cladosporol A, for the indicated times.
We also performed the same experiments by cultur-
ing the cells in D-MEM (or RPMI1640) containing
10% FBS and the results obtained were identical.
Cell Viability and Lipid Peroxidation Assays
The growth rate of HT-29 cells was evaluated
using the CellTiter Aqueous One Cell Proliferation
Assay (Promega, Madison, WI), following the man-
ufacturer’s procedure. Cells were seeded in 96-well
plates in order to reach the density of 106 cells/
cm2 in standard conditions (10% FBS). After 24 h,
increasing concentrations of cladosporol (from 0.4
to 75 mM) were added to stimulate cells and the
growth was evaluated from 24 up to 72 h. The in-
hibition rate was expressed as the optical density
ratio of the difference between the control and the
treated cells to the control. The concentration of
cladosporol A required for 50% reduction in cell
survival (IC50) was calculated using standard
curves. Each time point was done in triplicate and
the experiment repeated at least two times. The ab-
sorbance at 490 nm was measured on a microplate
reader (BenchMark, Bio-Rad, Hercules, CA).
To further evaluate cell growth after treatment
with cladosporol A, cells were plated in 12-well
plates at density of 106 cells/cm2. After treatment,
the cells were washed with PBS, trypsinized and
collected in culture medium. Cell counting was
performed by means of a Bu¨rker’s hemocytometer.
Three counts for each well were made and the mean
value and the standard deviation were calculated.
Lipid peroxidation products from cells were
measured by the thiobarbituric acid colorimetric
assay. Brieﬂy, an aliquot of the lysate (100 ml) was
added to 200 ml of 10% (w/v) trichloroacetic acid
and, after centrifugation at 3,000 rpm for 10 min,
260 ml of 0.5% (w/v) thiobarbituric acid were
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added and the mixture was heated at 80–1008C for
30 min. After cooling, malondialdehyde (MDA)
formation was recorded by spectrophotometry at
550 nm, in a microplate reader spectrophotometer
(Bio-Rad). The results are presented as micromoles
of MDA/mg of cell protein determined by the Bio-
Rad protein assay. A standard curve of MDA was
used to quantify the MDA levels formed during
the experiments.
Flow Cytometry Analysis
HT-29 cells were plated at similar conﬂuency, as
described above, and after 24 h, synchronized by a
48 h serum deprivation in 0.1% FBS. An aliquot of
the cells was stimulated with 5, 10, or 20 mM cla-
dosporol A for different times (4, 8, 12, 24, and
48 h) in the presence of D-MEM containing 10%
FBS. Another aliquot of cells was allowed to grow
again in the complete medium; these samples were
used as control. Afterwards, 2 millions of whole
ﬂoating and adherent cells of each sample were
collected, washed in cold calcium and magnesium-
free phosphate buffered saline (PBS), ﬁxed and per-
meabilized in 70% cold ethanol for 30 min. Etha-
nol was removed by washing with PBS and cells
were incubated in PBS containing 10 mg/ml deoxy-
ribonuclease-free ribonuclease, for 10 min, at 48C.
Finally, 50 mg/ml PI was added and the cells were
incubated at 48C, overnight, in a dark room. Cells
were analyzed by ﬂow cytometry using a FACScan
Flow Cytometer Apparatus 488 nm argon-laser
(Becton Dickinson, Mountain View, CA). Analysis
of the results was performed with CellFit DNA soft-
ware (version 2.01.2 Becton Dickinson) run on HP
series 9000 workstation Apollo OS Consort32
(Hewlett-Packard, Palo-Alto, CA). Width gating
was performed to exclude doublets from G2/M
region on dot-plot. For each sample, 2,000 events
were stored in list mode. The same experiment
was performed also using p53þ/þ and p53/
HCT116 cells.
Western Blotting Analysis and Kinase Assay
Treated and untreated cells were lysed in Ripa
buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.6,
10 mM EDTA, 1% NP-40) containing also protease
inhibitors cocktail and then centrifugated at
13,000 rpm for 10 min, at 48C. Supernatant con-
taining total proteins was quantiﬁed and 80 mg of
each sample were separated on 12% SDS–PAGE
and transferred onto a PVDF membrane (Millipore,
Bedford, MA) by electroblotting. Membranes were
blocked in 5% non-fat dry milk and probed with
speciﬁc antibodies at 48C, overnight. After a 1-h
incubation with IgG-peroxidase-linked antibody,
at room temperature, signals were detected by
chemiluminescence with ECL or ECL Plus reagents.
The relative intensity of protein bands was mea-
sured using the Molecular Imager Chemi-Doc
imaging system (Bio-Rad) and evaluated by the
Quantity One software (Bio-Rad).
To determine the histone H1-associated CDK2
kinase activity, 200 mg of protein lysates from each
sample was precleared with protein A/G plus aga-
rose beads and CDK2 was immunoprecipitated
using a speciﬁc anti-CDK2 antibody (2 mg) and
protein A/G plus agarose beads. The beads were
washed three times with lysis buffer and ﬁnally
twice with kinase assay buffer. Phosphorylation of
histone H1 was measured by incubating the beads
with 30 mg of ‘‘hot’’ kinase solution (4 mg of his-
tone H1, 1 ml of g-32P-ATP, 0.5 ml of 0.1 mM of
ATP and 24.5 ml of kinase buffer) for 1 h at 378C.
The reaction was stopped by boiling the samples
in SDS sample buffer for 5 min. The samples were
analyzed by 12% SDS–PAGE and the gel was dried
and subjected to autoradiography.
Reverse Transcription-PCR (RT-PCR) and Real-Time
Quantitative PCR (RT-qPCR) Assays
RNA was isolated from treated and untreated
HT-29 cells using TRIZOL reagent according to
the manufacturer’s instructions. The purity,
integrity, and concentration of total RNA were
determined by gel electrophoresis and UV spectros-
copy. To obtain the cDNAs, 2 mg of total RNA
were reverse transcribed using SuperScriptTM II re-
verse transcriptase. For each sample, total RNA
was incubated with 2.5 mM random primers at
708C, for 10 min. After this step, a mixture con-
taining 0.5 mM dNTP, 10 mM DTT, 5 U of Super-
ScriptTMII enzyme (Invitrogen, Carlsbad, CA) and
First Strand buffer was added to the sample, which
was incubated for 10 min, at room temperature.
Subsequently, the reaction proceeded at 428C, for
50 min and, ﬁnally, was stopped by incubation at
708C, for 15 min. PCR analysis was performed for
p21waf1/cip1 gene (351 bp amplicon) by using the
following primers: 50-GCGATGGAACTTCGACTT-
TGT-30 and 30-GGGCTTCCTCTTGGAGAAGAT-50.
As an internal control for the densitometric analy-
sis of the ampliﬁed fragments, the housekeeping
human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) gene (400 bp amplicon) was utilized
by using the following primers: 50-GACCCCTT-
CATTGACCTCAACTACATG-30 and 30-GTGCAC-
CACCCTGTTGCTGTA GCC-50. PCR reaction was
performed by adding to each sample a 20 ml mix-
ture containing 2 ml of the newly synthesized
cDNA, PCR Buffer II, 1.5 mM MgCl2, 0.2 mM dNTP,
0.2 mM primers, and 2.5 U of AmpliTaq1Gold
(Applied Biosystem, Foster City, CA). DNA ampliﬁ-
cation was carried out allowing 30 and 35 PCR
cycles of reactions (948C for 1 min, 588C for 30 s,
728C for 1 min, for each cycle). PCR products
were analyzed on 1.2% agarose gels containing
ethidium bromide. Gel images were acquired with
the Chemi-Doc imaging system (Bio-Rad).
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For RT-qPCR, a 20 ml mixture containing 1 mg of
cDNA, 10 ml of SYBR Green and 0.4 mM primers of
p21WAF1/Cip1 or GAPDH was added to each sample.
Thirty-ﬁve ampliﬁcation cycles were performed
according to the program used in RT-qPCR assay.
For each sample, analysis was carried out in tripli-
cate and the results were evaluated by the Gene
Expression Relative Quantitation program (Bio-Rad).
Plasmids and Transient Transfection Experiments
The human wild-type p21waf1/cip1 promoter-
luciferase fusion construct (pWWP) and the mutants
pWP124, pWP101, pWP101-mtSp1-3, pWP101-
mtSp1-4, pWP101-mtSp1-5/6 were a generous
gift from Dr. Y. Sowa (Department of Molecular-
Targeting Cancer Prevention, Kyoto Prefectural
University of Medicine, Kyoto, Japan) [35,36]. As
an internal transfection control, we used the RSV-
bGal plasmid, expressing b-galactosidase cDNA
driven by the strong Rous Sarcoma Virus (RSV)
promoter.
The day before transient transfection, HT-
29 cells were plated in 12-well plates to reach a
70% conﬂuence. After 24 h, growth medium was
replaced with OPTI-MEM1I, (Gibgo, Carlsbad, CA)
without serum and antibiotics, and cells were
transfected using lipofectamine 2000 reagent
according to manufacturer’s instructions. About
10–12 h after transfection, cells were washed and
treated with 20 mM cladosporol A. Transfection
samples were carried out in triplicate and the
transactivation activities were evaluated by lucifer-
ase assay. The achieved values were normalized
by b-galactosidase assay and the average value for
each triplicate was calculated.
Bi-Dimensional Electrophoresis
HT-29 cells were plated at 40% conﬂuence and
treated or not with 20 mM cladosporol A for 8 h.
Treated and untreated cells were collected into a
buffer containing 8 M urea, 4% CHAPS, 40 mM
Tris, 65 mM DTT and Protease Inhibitors cocktail,
and lysed by three cycles of sonication at 70% am-
plitude. After centrifugation at 13,000 rpm for
30 min, at 48C, total proteins were extracted and
quantiﬁed by spectroscopy at 595 nm. For each
sample, 200 mg of total proteins were solubilized
in a buffer with 8 M urea, 2% CHAPS, 100 mM
DTT, 0.5% ampholytes, and analyzed. For isoelec-
trofocusing, 7 cm strips with a 4–7 pH range were
used; strip rehydration proceeded for 16 h. The
focusing system was the IPG (GE Healthcare, Chal-
font St. Giles, UK) and the program was set at an
increasing voltage until 1,000 V for 1 h and then
until 5,000 V for 160 min, at 208C. Afterwards, the
strips were equilibrated in 50 mM Tris–HCl, pH
8.8, 2% SDS, 7 M urea, 10% glycerol, 2% DTT, for
15 min, and then incubated in 50 mM Tris–
HCl, pH 8.8, 2% SDS, 7 M urea, 10% glycerol,
2.5% iodoacetamide, bromophenol blue, for
15 min. Each strip was accommodated onto a 12%
polyacrylamide gel and the proteins were separated
at 120 V, for 3 h. Gels were ﬁxed in 7% acetic acid,
50% methanol, for 15 min, and stained with Gel
Code Blue Stain reagent (Pierce, Thermo Fisher
Scientiﬁc, Rockford, IL). Gels were scanned with a
GS-800 calibrated densitometer (Bio-Rad) and ana-
lyzed by using the PD Quest v.6 software. The Spot
Detection Wizard function allowed to optimize the
spot determination parameters, to quantify relative
intensity of all spots and evaluate statistical signiﬁ-
cance of the measured data. Spots intensities
were obtained in pixel units and normalized to
the total absorbance of the gel. Signiﬁcance of dif-
ferences between data was tested with the non-
parametric Kolmogorov–Smirnov test. Since data
were normally distributed, standard deviations
of these distributions were a valid parameter to
assess the signiﬁcance of the quantitative differen-
ces measured. The maximal value of mean and
median of logarithmic ratios of standard devia-
tions was 0.1, thus a threefold value of this param-
eter was used as a cut-off criterion to identify
differentially expressed proteins. The increasing/
decreasing index (fold change) was calculated as
ratio of averaged spot intensities (relative volumes)
between the investigated and control maps.
Two biological replicates of each sample and three
technical replicates of each biological replicate
were analyzed.
In Gel Digestion and Mass Spectrometry (MS) Analysis
Spots were manually excised from gels, triturated
and washed with water. Proteins were in-gel re-
duced, S-alkylated and digested with trypsin as
previously reported [37]. Digest aliquots were re-
moved and subjected to a desalting/concentration
step on mZipTipC18 (Millipore) using 5% formic
acid/50% acetonitrile as eluent before MALDI-TOF-
MS or nanoLC-ESI-LIT-MS/MS analysis.
In the ﬁrst case, peptide mixtures were loaded
on the MALDI target, using the dried droplet tech-
nique and a-cyano-4-hydroxycinnamic acid as ma-
trix, and analyzed by a Voyager DE PRO mass
spectrometer (Applied Biosystems, Framingham,
MA), operating in positive ion reﬂectron mode,
with an acceleration voltage of 20 kV, a nitrogen
laser (337 nm) and a laser repetition rate of 4 Hz.
The ﬁnal mass spectra, measured over a mass range
of 800–4,000 Da and by averaging 50–300 laser
shots, were elaborated using the DataExplorer 5.1
software (Applied Biosystems) and manually
inspected to get the corresponding peak lists. Inter-
nal mass calibration was performed with peptides
deriving from trypsin autoproteolysis.
In the second case, after removing acetonitrile
by concentration, digests were analyzed by
nanoLC-ESI-LIT-MS/MS using a LTQ XL mass
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spectrometer (Thermo Finnigan, San Jose, CA)
equipped with Proxeon nanospray source con-
nected to an Easy-nanoLC (Proxeon, Odense,
Denmark). Peptide mixtures were separated on an
Easy C18 column (10  0.075 mm, 3 mm) (Prox-
eon, Odense, Denmark) using a linear gradient
from 5% to 50% of acetonitrile in 0.1% formic
acid, over 60 min, at a ﬂow rate of 300 nl/min.
Spectra were acquired in the range m/z 400–2000.
Acquisition was controlled by a data-dependent
product ion scanning procedure over the three
most abundant ions, enabling dynamic exclusion
(repeat count 2 and exclusion duration 1 min).
The mass isolation window and collision energy
were set to m/z 3 and 35%, respectively.
Protein Identification
MASCOT software package (Matrix Science, UK)
was used to identify spots unambiguously from an
updated plant non-redundant sequence database
(NCBI nr 2009/05/03) in MALDI-TOF peptide mass
ﬁngerprinting experiments by using a mass toler-
ance value of 40–80 ppm, trypsin as proteolytic en-
zyme, a missed cleavages maximum value of 2 and
Cys carbamidomethylation and Met oxidation as
ﬁxed and variable modiﬁcation, respectively. Can-
didates with a MASCOT score > 82, corresponding
to P < 0.05 for a signiﬁcant identiﬁcation, were
further evaluated by the comparison with their cal-
culated mass and pI values, using the experimental
values obtained from 2-DE.
MASCOT software package (Matrix Science, UK)
was also used to identify spots unambiguously
from the same updated plant non-redundant se-
quence database (NCBI nr 2009/05/03) in nanoLC-
ESI-LIT-MS/MS experiments by using a mass toler-
ance value of 2 Da for precursor ion and 0.8 Da for
MS/MS fragments, trypsin as proteolytic enzyme, a
missed cleavages maximum value of 2 and Cys car-
bamidomethylation and Met oxidation as ﬁxed
and variable modiﬁcation, respectively. Candidates
with more than two assigned peptides with an in-
dividual MASCOT score >25, corresponding to
P < 0.05 for a signiﬁcant identiﬁcation, were fur-
ther evaluated by the comparison with their calcu-
lated mass and pI values, using the experimental
values obtained from 2-DE. Where appropriate,
protein identiﬁcation was checked manually to
provide for a false positive rate <1%.
Statistical Analysis
All experiments were performed at least three
times. Data from viability and lipid peroxidation
assays, ﬂow cytometry, Western blotting, RT-PCR,
and transient transfection experiments were exp-
ressed as means  SD. Statistical signiﬁcance was
determined by Student’s test comparison between
two groups of data sets. Asterisks reported in the
ﬁgures show the differences of experimental
groups in comparison with the corresponding con-
trol condition (P < 0.05, for example).
RESULTS
Cladosporol A Inhibits the Growth of Different Human
CRC Cell Lines
To examine the effects of cladosporol A on cell
growth, we initially treated colon carcinoma HT-
29 cells for 72 h with increasing concentrations of
the compound. Cell survival was reduced as evalu-
ated by the CellTiter Aqueous One Cell Prolifera-
tion Assay (Figure 1B). The IC50 values of
cladosporol A on HT-29 cells were 13.85, 12.35,
and 6.9 mM following a 24, 48, and 72 h treat-
ment, respectively. On the basis of these values,
we tested the antiproliferative effect of cladosporol
A on two additional CRC derived cell lines, CaCo-
2, SW480, in parallel with HT-29. Cells were
treated with increasing amounts of cladosporol A
for 24 h and their proliferation rate was reduced in
a dose-dependent manner (Figure 2A). HT-29
showed a more evident growth inhibition than
SW480 and CaCo-2 cells and were analyzed in
details in the following experiments. We then
treated HT-29 cells with increasing concentrations
of cladosporol A, for 4, 8, 24, and 48 h. The num-
ber of surviving cells diminished in a dose- and
time-dependent manner, as compared to untreated
cells (Figure 2B). Cladosporol A did not exert a ge-
neric cytotoxic effect on HT-29 cells because inhi-
bition was reverted following drug withdrawal.
Growth recovery was even more evident when
cells were treated for 24 or 48 h with the drug
(5 mM) and then left in culture for additional 96 h
in the absence of the drug (Supplementary data1).
These results are consistent with those reported by
Chen et al. [33] who showed no toxicity induced
by cladosporol in gastric cancer cells xenografted
into nude mice. Finally, cladosporol A-treated cells
detached from the plate surface with a typical
rounded-up morphology as observed with a light
transmission microscope (Figure 2C). All together,
these ﬁndings indicate that cladosporol A inhibits
the proliferative capacity of various CRC tumor
cell lines, among which HT-29 cells were the most
susceptible to treatment.
Cladosporol A Induces a G1-Phase Growth Arrest During
the Cell Cycle
To determine the cell cycle changes underlying
the growth inhibition found, the nuclear DNA
content of HT-29 cells at the different phases
of the cell cycle was analyzed by ﬂow cytometry
in the absence or presence of cladosporol A. HT-
29 cells were cultured in proliferating medium
for 24 h and, subsequently, synchronized by
serum starvation for 48 h. Cells were then grown
in a medium containing 10% FBS and different
6 ZURLO ET AL.
Molecular Carcinogenesis
Figure 2. Cladosporol A inhibits cell growth in a dose– and
time–response manner. (A) To assess the effect of cladosporol A
on esponentially growing HT-29, CaCo-2, and SW480 cells, cells
were treated with different doses of cladosporol A (5, 10, and
20 mM). After 24 h, cells were collected and counted. The data
shown here are mean  SD of three experiments performed in du-
plicate. Results were similar in two independent experiments.P < 0.05; P < 0.01; P < 0.005 when compared with con-
trol. (B) To assess the effect of cladosporol A on esponentially
growing HT-29 cells, cells were treated or not with 5, 10, and
20 mM cladosporol A, for 4, 8, 24, and 48 h. Then, cells were
collected and counted. The data shown here are mean  SD of
three experiments performed in duplicate. Results were similar in
two independent experiments. P < 0.05 when compared with
control. (C) Morphological changes of HT-29 cells treated or not
with 5, 10, and 20 mM cladosporol A. Pictures were taken using
light trasmission microscopy at a magniﬁcation of 10.
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concentrations of cladosporol A. Exposure to 5–
10 mM of the compound determined a signiﬁcant
increase in the G2/M cell population and a con-
comitant decrease in the G1-phase cells with re-
spect to untreated cells (Figure 3A). Speciﬁcally,
treatment with 5 and 10 mM cladosporol A for
24 h resulted in 29.45% and 34.45% of G2/M cells,
respectively, as compared to 19.1% of control cells
(Table 1). Exposure to 20 mM cladosporol A, sur-
prisingly, caused a signiﬁcant increase of G1 cells
and a parallel decrease of the S and G2/M cell
population. The percentage of G1 cells was 60.2%
at 12 h and 57.1% at 24 h as compared to 34.9%
and 47.65% in control cells, respectively (Table 1).
Cladosporol A then affects HT-29 cell proliferation
ability through a cell cycle arrest at the G2/M
phase at 5–10 mM or at the G1 phase at higher
dosages.
We next examined whether the cell cycle arrest
was associated with changes in the expression
of speciﬁc proteins involved in its control
(Figure 3B,C). To this aim, total protein extracts
Figure 3. Cladosporol A suppresses HT-29 cells via G1-phase ar-
rest. (A) Cell cycle distribution in HT-29 cells, ﬁrstly synchronized
by serum deprivation and then treated or not with 5, 10, and
20 mM cladosporol A, for 4, 8, 12, 24, and 48 h. Data are
mean  SD of three different experiments performed in duplicate.
(B) Western blotting analysis on total protein extracts produced
from HT-29 cells treated or not with 5 and 20 mM cladosporol A
for 12, 24, and 48 h. Anti-p21waf1/cip1 was used to probe untreat-
ed and cladosporol A-treated HT-29 cells. Lane 1: proliferating
cells; lane 2: serum-deprived cells. In lanes 4 and 6 of left panel
and lanes 3, 5 and 7 of the right panel are reported the results
from untreated HT-29 cells. In lanes 3, 5 and 7 of left panel and
lanes 4, 6, and 8 of right panel are reported the results from HT-
29 cells treated with the speciﬁc dosages for the indicated times.
(C) The same samples of (B) were tested by Western blotting
experiments with an anti-cyclin D1 antibody. Lane 1: proliferating
cells; lane 2: serum-deprived cells. In lanes 4 and 6 of left and right
panels are reported the results from untreated HT-29 cells. In lanes
3, 5, and 7 of left and right panels are reported the results from
HT-29 cells treated with the speciﬁc dosages for the indicated
times. To normalize the samples loaded on the gel, Western blot-
ting with an anti-b-actin antibody was carried out.
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from HT-29 proliferating (lane 1), serum-deprived
(lane 2), treated with 5 mM (lanes 3, 5, and 7, left
panel) and 20 mM cladosporol A (lanes 4, 6, and 8,
right panel), for 12, 24, and 48 h, were probed for
p21waf1/cip1 by Western blotting and compared to
untreated control cells (lanes 4 and 6 for the 5 mM
dosage, left panel; lanes 3, 5, and 7 for the 20 mM
dosage, right panel). p21waf1/cip1 was expressed at
high levels in HT-29 cells treated with 20 mM cla-
dosporol A for 12 h (Figure 3B, right panel lane 4),
and only modestly in proliferating cells (lane 1)
and corresponding controls at 12, 24, and 48 h
(lanes 3, 5 and 7). The expression remained elevat-
ed in cells exposed to 20 mM cladosporol A for
24 and 48 h (lanes 6 and 8), although progressively
diminished, suggesting degradation events. In se-
rum-deprived cells, p21waf1/cip1 expression was
only slightly increased, as expected (lane 2). Cyclin
D1 expression was lower in cells treated for 24
and 48 h with 20 mM cladosporol A (lanes 5 and 7)
than the untreated controls (lanes 4 and 6), con-
ﬁrming the speciﬁc G1-phase block (Figure 3C,
right panel). No changes in p21waf1/cip1 or cyclin
D1 protein expression were observed in HT-29 cells
exposed to 5 mM cladosporol A, in agreement with
the ﬂow cytometry data (see Figure 3A–C). Thus,
the treatment with 20 mM cladosporol A causes a
G1 phase arrest as documented by the increase in
p21waf1/cip1 expression and the simultaneous de-
crease of cyclin D1.
Cladosporol A Influences the Expression of Cell Cycle
Regulators in Proliferating HT-29 Cells
We then treated proliferating HT-29 cells for dif-
ferent times with increasing concentrations of
cladosporol A and assessed the expression of spe-
ciﬁc proteins involved in cell-cycle control. Expres-
sion of p21waf1/cip1, cyclin A and B1, speciﬁc
markers of G1, S, and G2/M phases, respectively,
was investigated by Western blotting assay. Expo-
sure to 5–10 mM cladosporol A for 4 and 8 h,
resulted in a modest increase of p21waf1/cip1, where-
as the treatment with 20 mM cladosporol A, for the
same times, caused a robust accumulation of
p21waf1/cip1 (Figure 4). From 8 h of treatment,
p21waf1/cip1 started to decline to reach undetectable
levels at 48 h. Cyclin B1 expression increased in a
dose (5, 10, and 20 mM) and time dependent man-
ner (4, 8, and 24 h), recovering the control levels
at 48 h. Cyclin A expression, on the contrary, rap-
idly diminished already at 4 h of treatment with 5,
10, and 20 mM cladosporol A, with no detectable
variations at 8, 24, and 48 h.
Since p21waf1/cip1 accumulates in proliferating
HT-29 cells after only 4 h of cladosporol A expo-
sure, we next investigated whether other cell cycle
regulators were affected under the same experi-
mental conditions. Cells were treated with 20 mM
cladosporol A, for 4, 6, and 8 h, and protein
extracts analyzed by Western blotting for different
cell cycle gatekeepers (Figure 5A–I). In addition to
the growth arrest, accumulation of p21waf1/cip1 pro-
tein (about twofold as compared to control) and
progressive decrease of cyclin D1 as shown above,
cyclin B1 showed a light increase while Cdc2-p34
and PCNA slightly decreased suggesting a partial
accumulation of cells at the G2/M phase. This
block occurred even if the treatment with 20 mM
cladosporol A was associated with a G1 phase ar-
rest. Moreover, cyclin E, CDK2, CDK4 also showed
Table 1. The Percentage of HT-29 cells in Each Population During the Cell Cycle is Reported as the Mean  SD of
Three Different Experiments Performed in Duplicate
0 h 4 h 8 h 12 h 24 h 48 h
Untreated
G0/G1 60.6  1.1 56.5  2.25 59.55  1.75 34.9  1.9 47.65  0.15 16.55  0.65
S 29.1  3.1 28.45  1.25 25.04  1.4 52.8  3 33.2  0.00 41.5  0.2
G2/M 10.3  2 15.5  1 15.45  0.45 12.3  1.1 19.1  0.1 12.0  0.5
5 mM
G0/G1 60.6  1.1 58.25  10.85 51.9  3 36.15  0.65 35.5  0.9 54.9  1.1
S 29.1  3.1 24.6  3.4 21.25  0.95 37.2  6.5 35.1  1.2 33.35  2.15
G2/M 10.3  2 18.05  8.35 26.85  3.95 26.6  5.8 29.45  2.05 11.75  1.05
10 mM
G0/G1 60.6  1.1 51.75  2.25 57.85  0.95 55.4  1.9 20.3  7.2 47  7.7
S 29.1  3.1 29  1 18.1  3.1 19.8  4.4 45.3  8.4 38.6  5.5
G2/M 10.3  2 19.05  0.95 24.05  4.05 24.8  2.5 34.45  0.15 14.4  2.2
20 mM
G0/G1 60.6  1.1 59.65  3.55 62  1.4 36.15  0.65 35.5  0.9 54.9  1.1
S 29.1  3.1 24.35  1.25 22.65  0.35 52.8  3 33.2  0.00 41.5  0.2
G2/M 10.3  2 17.7  6.8 15.35  1.75 18.5  0.00 14.9  1.3 16  1.5
For all treated samples P-values were calculated (P < 0.05 when compared with control).
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a time-dependent decrease indicating that inhibi-
tion of cyclinD1/CDK4 and cyclinE/CDK2 com-
plexes might explain the cladosporol A-induced
G1 phase cell cycle arrest (Figure 5F–H). As shown
in Figure 5L, treatment of HT-29 cells with 20 mM
of cladosporol A resulted in a reduction in histone
H1-associated CDK2 activity that could be due to
the cyclin E and CDK2 decrease, and simultaneous
increase of cyclinE/CDK2 complex binding to
CDKIs, that is, p21waf1/cip1. Lastly, RB, which is the
target of the cyclinD1/CDK4, showed a signiﬁcant
reduction after cladosporol A treatment, suggesting
a diminished availability to the binding with
cyclinD1/CDK4 complex (Figure 5I). Together,
these results indicate that cladosporol A is respon-
sible for the changes in cell cycle regulators
not only in synchronized, but also in proliferating
HT-29 cells and, remarkably, that the cladosporol
A-induced G1 phase cell cycle arrest in HT-29 cells
could be sequentially caused by induction of
CDKIs (p21waf1/cip1), a decrease of G1 phase cyclins
and CDKs and, ﬁnally, a decrease in the histone
H1-associated CDK2 kinase activity.
Cladosporol A Up-regulates p21waf1/cip1 Transcription in
HT-29 Cells
To investigate whether the p21waf1/cip1 increase
was due to a gene transcription activation, total
RNA was extracted from HT-29 cells treated
with 20 mM cladosporol A, for 1, 2, 4, and 8 h,
and analyzed by semiquantitative RT-PCR. The
p21waf1/cip1 speciﬁc amplicon showed a sharp in-
crease after 2 h reaching a plateau at 4 and 8 h
(Figure 6A). Similar results were obtained by carry-
ing out longer PCR assays (30 vs. 35 cycles)
(Figure 6B). A more accurate analysis by RT-qPCR
further supported these results as illustrated in
Figure 6C.
To conﬁrm that cladosporol A induces a more
efﬁcient p21waf1/cip1 gene transcription, we tran-
siently transfected proliferating HT-29 cells with a
recombinant plasmid (pWWP) bearing the entire
p21waf1/cip1 human gene promoter, a 2,320 bp long
fragment, fused upstream to the luciferase reporter
gene [38]. Exposure of transfected HT-29 cells to
20 mM of cladosporol A caused an increase in lucif-
erase activity as compared to untreated cells
(Figure 6D). Note that no luciferase activity was
detected at higher cladosporol A concentrations
indicating that transcription inhibition is likely
due to a drug saturation effect. As a positive con-
trol, an aliquot of transfected cells was exposed to
10 mM troglitazone, a member of the thiazolidine-
diones (TZD) family of PPARg speciﬁc ligands. In
fact, it is known that the human p21waf1/cip1 gene
is positively regulated through the interaction of
the transcription factor Sp1 with PPARg5 a mem-
ber of the orphan nuclear receptors family [38–40],
particularly in thyroid cells [41].
To investigate whether the Sp1 binding sites lo-
cated in proximal promoter play any role in medi-
ating cladosporol A-induced p21waf1/cip1 gene
transcription, we transiently transfected a reporter
construct (pWP124) that includes only the more
proximal 124 bp of the p21waf1/cip1 promoter and
no longer carries the two p53 binding sites located
at position 2301 and 1394 and the two RXR
motifs at 1221 (RXRE1) and 1198 (RXRE2), re-
spectively (Figure 6E). Luciferase activity in cells
treated with cladosporol A was higher than that
observed in cells transfected with the reporter plas-
mid carrying the entire promoter (pWWP), sug-
gesting that the transcriptional efﬁciency of the
human p21waf1/cip1 promoter depends on the pres-
ence of the Sp1 binding motifs located within the
proximal promoter. Neither the binding of p53
nor that of RXR to their cognate motifs in the
more upstream promoter appear to be required for
cladosporol A-induced p21waf1/cip1 transcription.
To understand the relative contribution of
the Sp1 binding sites to gene activation, we tran-
siently transfected recombinant plasmids in which
the Sp1 binding sites were either deleted or site-
directed mutated (Figure 6E). Plasmid pWP101,
carrying a shorter version of the p21waf1/cip1 pro-
moter in which the two more upstream Sp1
Figure 4. Effect of cladosporol A on the cell cycle regulators expression in proliferating HT-29 cells treated or
not with 5, 10, and 20 mM cladosporol A, for 4, 8, 24, and 48 h. Different antibodies against p21waf1/cip1, cyclin
B1 and cyclin A, three modulators of G1, S, and G2/M phases, respectively, were used in the Western blotting
analysis. To control the samples loaded derived from untreated and cladosporol A-treated HT-29 cells, an anti-
b-actin antibody was used. Cells were treated with the speciﬁc dosages for the indicated times.
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Figure 5. Quantitative evaluation of the cladosporol A-induced
expression of the cell cycle regulators in proliferating HT-29 cells.
Cells were treated or not with 20 mM cladosporol A, for 4, 6, and
8 h. Cell lysates were prepared in non-denaturing lysis buffer and
then analyzed by Western blotting using anti-p21waf1/cip1 (A), anti-
cyclin B1 (B), anti-cyclin D1 (C), anti-Cdc2-p34 (D), anti-PCNA (E),
anti-cyclin E (F), anti-CDK2 (G), anti-CDK4 (H), anti-RB (I) antibod-
ies. To control the samples loaded derived from untreated and
cladosporol A-treated HT-29 cells, an anti-b-actin antibody was
used. The bar graphs represent the mean  SD of proteins/b-actin
of at least three independent experiments. The Western blotting
assays reported here are representative of a single exempliﬁcative
experiment. (L) Histone H1-associated CDK2 kinase activity assay in
proliferating HT-29 cells. Cells were treated with 20 mM clado-
sporol A for the indicated times and then total cell lysates of each
sample were immunoprecipitated with anti-CDK2 antibody. The
kinase reaction was performed using histone H1 as substrate of
cyclin E/CDK2 complex. The bar graphs represent the mean  SD
of at least three independent experiments, while the assay reported
here is representative of a single exempliﬁcative experiment.
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binding sites (Sp1-1 and Sp1-2) were deleted,
was still able to respond to 20 mM cladosporol A-
treatment with an increase of luciferase activity
similar to that observed with plasmids pWP124
and pWWP. Transfection of the pWP101-mtSp1-3,
in which the third Sp1 binding site is mutated,
caused only a slight induction of luciferase activi-
ty. Plasmid pWP101-mtSp1-4 with a mutated bind-
ing site 4 did not affect the luciferase activity
increase of the intact 124 bp long promoter,
Figure 6. Cladosporol A treatment induces the p21waf1/cip1 gene
transcription. (A) mRNA expression of p21waf1/cip1 in HT-29 cells
evaluated by semiquantitative RT-PCR. Total RNA extracted from
proliferating HT-29 cells treated or not with 20 mM of cladosporol
A, for 1, 2, 4, and 8 h, was used to amplify the speciﬁc p21waf1/cip1
351 bp-long product for 30 cycles. Ampliﬁcation of the GAPDH
gene was used as internal control. (B) The same total RNA samples
of (A) were used to amplify the speciﬁc p21waf1/cip1 351 bp-long
ampliﬁcation product for 35 cycles. Ampliﬁcation of the GAPDH
gene was used as internal control. (C) Real-time RT-qPCR was per-
formed using total RNA extracted from proliferating HT-29 cells
treated or not with 20 mM of Cladosporol A for 1, 2, 4, and 8 h.
The bar graphs represent the mean  SD of p21waf1/cip1/GAPDH
produced after three independent experiments. (D) Cladosporol A
induces transcriptional activity of p21waf1/cip1 promoter gene. HT-
29 cells were transiently transfected with the wild-type p21waf1/cip1
promoter-luciferase plasmid (pWWP) reported in panel E and
treated with 10, 20, and 40 mM of cladosporol A for 24 h. TZD
(10 mM) was used as positive control of p21waf1/cip1 promoter tran-
scriptional activity. Luciferase activities were normalized to the b-
galatosidase ones used as control. Data shown are mean  SD of
three independent experiments performed in duplicate. (E) Func-
tional analysis of the transcriptional activity of p21waf1/cip1 promot-
er gene by deletion and site-directed mutagenesis. Left: structural
features of the recombinant plasmids carrying the mutated forms
of the p21waf1/cip1 promoter used in this study. Right: results of the
transiently transfections in HT-29 cells as fold induction of lucifer-
ase activity and obtained with the p21waf1/cip1 promoter-luciferase
plasmids reported in the left panel. Cells were treated with 20 mM
of cladosporol A for 24 h. The luciferase activities were normalized
to the b-galatosidase ones used as control. Data shown are
mean  SD of three independent experiments performed in
duplicate.
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whereas plasmid pWP101-mtSp1-5/6 with mutated
Sp1 binding sites 5/6 caused a very low, if any,
luciferase activity. These results indicate that the
two more upstream Sp1 binding sites do not
affect p21waf1/cip1 transcriptional efﬁciency, while
the Sp1 binding sites 3 and 5/6 appear to play a
central role in mediating the formation of a tran-
scriptional apparatus capable to promote gene
expression.
Cladosporol A Treatment of HT-29 Cells Induces
an Oxidative Stress-Response and Activates the
MAPK Pathways
To further investigate the protein variations in-
duced by cladosporol A in HT-29 cells, a proteomic
analysis was performed on cells treated or not with
20 mM cladosporol A for 8 h. Total protein extracts
were separated on PAGEs covering a 4–7 pH range
and 10–150 kDa Mr ranges, followed by a Coomas-
sie-based reagent staining. All gel images from
treated and untreated cells were acquired and
quantitatively evaluated (Supplementary data 2).
About 30 spots showed at least a twofold differ-
ence in relative absorbance between samples; 21
spots were associated to protein sequence entries
by different MS approaches (Supplementary data
3). Chaperones, structural proteins, transcription
and translation factors, cell cycle regulators, redox
response modulators and apoptotic proteins were
identiﬁed among those whose expression changes
after cladosporol A treatment.
To conﬁrm that the protein changes observed
after drug treatment were dependent upon an
oxidative stress response, total protein extracts
from proliferating HT-29 cells exposed to 20 mM
cladosporol A, for 4, 6, and 8 h were analyzed
by Western blotting with antibodies recognizing
the phosphorylated forms of ERK and JNK. Both
proteins increased after treatment (Figure 7A,B).
To demonstrate that both signaling pathways
mediate the cladosporol A-induced redox response,
we then treated HT-29 cells as above in the
presence or absence of increasing concentrations
of NAC (N-acetyl-cysteine), an inhibitor of redox
species accumulation. Exposure to 20 mM clado-
sporol A caused a simultaneous increase in
p21waf1/cip1, pERK, and pJNK, while addition of
increasing concentrations of NAC counteracted
the drug-induced increase of the three proteins
(Figure 7C).
To further prove the redox species enhancement
by cladosporol A treatment, we assessed MDA pro-
duction through a lipid peroxydation assay as well
as the involvement of the NADPH oxydase, the
main enzymatic machinery responsible of ROS
generation. An increase in the production of reac-
tive species was ﬁrstly observed, conﬁrming that
cladosporol A induces a redox response (Supple-
mentary data 4A). Afterwards, we analyzed
whether the cladosporol A-induced ROS genera-
tion was prevented by the NADPH oxidase
speciﬁc inhibitor apocynin. The results shown in
Supplementary data 4B demonstrate that preincu-
bation with apocynin, before cladosporol A expo-
sure, results in a reduced p21waf1/cip1 expression,
suggesting that cladosporol A induces NADPH oxi-
dase-dependent ROS generation.
Finally, to further demonstrate the functional
link between ERK pathway and p21waf1/cip1
expression, we treated HT-29 cells with two MEK
inhibitors, PD98059 and UO126. The results
indicated that p21waf1/cip1 was up-regulated only
when the pathway is functional; when pERK was
blocked, no p21waf1/cip1 increase was observed
(Figure 7D).
These results provide the ﬁrst evidence that ERK
(and JNK also) might function as mediator of the
cladosporol A-induced inhibition of HT-29 cell
growth. Although additional experiments must
be performed to clarify the interplay between the
different signaling pathways activated by clado-
sporol A, our preliminary data suggest that the mi-
togen-activated protein kinase (MAPK) pathways
are involved in the cladosporol A-induced regula-
tion of HT-29 cells proliferation.
DISCUSSION
In this paper, we provide evidence that clado-
sporol A displays antiproliferative activity in
human CRC derived cell lines, speciﬁcally in HT-
29 cells (Figures 1B and 2A–C). The inhibition of
cell proliferation is reversible at lower doses (5 and
10 mM), as the cells can escape the cell cycle arrest;
in contrast, cell proliferation is irreversibly reduced
at higher doses (20 mM) (Figure 2B), suggesting
that cladosporol A could act as a cytostatic rather
than a cytotoxic compound in human CRC de-
rived cells (Figure 2B and Supplementary data 1).
Similar results were obtained in other cell lines of
the same origin; the effects were more pronounced
in HT-29, likely due to their different genotypes
that could impart a different response to the
drug (for details see in Materials and Methods
Section).
Inhibition of cell growth by cytostatic agents is
generally accompanied by a cell cycle arrest at spe-
ciﬁc phases. Higher doses of cladosporol A were as-
sociated with a speciﬁc G1 phase arrest, while,
surprisingly, lower doses were associated with cell
accumulation at the G2/M phase (Figure 3 and
Table 1). Other molecules can cause both a G1
and a G2/M arrest at different concentrations.
Quercetin, a ﬂavonoid derived from grape, caper,
red onion, and green tea, induces a G2/M arrest at
lower (14.8 mM) and a G1 arrest at higher concen-
trations (52.1 mM) [42]. Silibinin, the major com-
ponent of milk thistle extract isolated from
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Sylibum marianum, on the contrary, induces a G1
arrest at lower concentrations (50 and 75 mM),
whereas provokes a G2/M block at higher concen-
trations (100 mM) [43].
The G2/M phase arrest that mainly occurs
in cells bearing DNA damages, allows these
injuries to be repaired before cells proceed
into mitosis, thereby preventing the stabilization
of the mutations. Accumulation of cells at the
G2/M phase observed with lower dosage suggests
that cladosporol A somehow inhibits DNA
replication.
Figure 7. Cladosporol A treatment of HT-29 cells induces an oxi-
dative stress–response and activates the MAPK pathways. Cells
were treated or not with 20 mM cladosporol A, for 4, 6, and 8 h.
Cell lysates were prepared in non-denaturing lysis buffer and then
analyzed by Western blotting using antibodies speciﬁcally recogniz-
ing the phosphorylated forms of ERK (A) and JNK (B) or b-actin
(control). The bar graphs represent the mean  SD of pERK or
pJNK/b-actin of three independent experiments. Western blotting
assays reported here are representative of a single exempliﬁcative
experiment. (C) Cells were treated or not with 20 mM cladosporol
A, for 4 h in absence and presence of increasing concentrations of
NAC (N-acetyl-cysteine). Cell lysates were prepared in non-denatur-
ing lysis buffer and then analyzed by Western blotting using
antibodies speciﬁcally recognizing the phosphorylated forms of
p21waf1/cip1, pERK, and pJNK. The bar graphs represent the
mean  SD of p21waf1/cip1 or pERK or pJNK/b-actin of three inde-
pendent experiments. Western blotting assays reported here are
representative of a single exempliﬁcative experiment. (D) Cells
were treated or not with 20 mM cladosporol A, for 4 h in absence
and presence of UO126 10 mM and PD98059 50 mM. Cell lysates
were prepared in non-denaturing lysis buffer and then analyzed by
Western blotting using antibodies speciﬁcally recognizing p21waf1/
cip1 and pERK. The bar graphs represent the mean  SD of p21 or
pERK /b-actin of three independent experiments. Western blotting
assays reported here are representative of a single exempliﬁcative
experiment.
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On the contrary, at higher dosage, cladosporol A
hits different molecular targets as documented by
changes in the expression of p21waf1/cip1 and cyclin
D1 (Figure 3). p21waf1/cip1 is considered as the uni-
versal inhibitor of cell cycle progression: it is up-
regulated in G1 and in G2/M phase and this bi-
modal periodicity of expression suggests a role in
the control of both phases of the cell cycle [44].
The robust increase in p21waf1/cip1 expression,
which we found in cells blocked at G1 phase, like-
ly indicates that, in our case, p21waf1/cip1 exerts its
effect in this phase (Figure 3B).
In proliferating HT-29 cells, indeed, we also
found a remarkable reduction in cyclin D1, cyclin
E, CDK2, and CDK4 expression after cladosporol
A treatment (Figures 4 and 5), proteins largely
involved in the G1/S restriction point control.
All together, a down-expression of cyclin D1,
cyclin E, CDK2, and CDK4 and a simultaneous
over-expression of p21waf1/cip1 appears to inﬂuence
the p21waf1/cip1 ability to bind the cyclinE/CDK2
complex and, consequently, to generate a reduced
kinase activity. The data reported in Figure 5L
demonstrate that the cyclinE/CDK2 complex,
that peaks at G1/S transition and usually phos-
phorylates several proteins, after cladosporol A
treatment, is not longer able to phosphorylate
the histone H1, conﬁrming the inhibition of
the G1/S transition and the cell cycle arrest in HT-
29 cells.
In proliferating HT-29 cells, the increased
p21waf1/cip1 expression is accompanied by reduced
levels of cyclin D1 and PCNA (Figures 3–5), con-
ﬁrming the role they play in regulating the G1/S
progression. Indeed, p21waf1/cip1 binds the cyclin
D1-CDK4/CDK6 complexes and inhibits their ki-
nase activity toward RB protein, stimulating a pro-
teasomal degradation of the complexes and
promoting a proliferation arrest [45]. Since we
found a reduced expression of RB protein expres-
sion after cladosporol A treatment (Figure 5I), it is
conceivable that this event results in an attenuated
RB-associated cyclin D1/CDK4 kinase activity.
p21waf1/cip1 is also a strong inhibitor of the DNA
polymerase auxiliary protein, PCNA, through its
carboxy-terminal domain [46]. The diminished ex-
pression of PCNA, shown in Figure 5E, is the dem-
onstration of the cladosporol A-induced action of
p21waf1/cip1.
Cyclin B1 and Cdc2-p34, known markers of
the G2/M arrest, are also reduced, suggesting that
cladosporol A at higher doses probably overcomes
the effects induced by lower doses (Figure 5B,D).
However, we cannot exclude that, even at
higher doses, HT-29 cells are partially arrested at
the G2/M phase as documented by the reduction
of the Cdc2-p34 protein (Figure 5D). More
experiments are required to study the detailed
mechanisms by which cladosporol A inhibits HT-
29 cell proliferation through the G2/M phase
arrest.
p21waf1/cip1 expression is ﬁnely regulated by
different mechanisms at the post-transcriptional
level; however, the most efﬁcient way to modulate
its expression occurs at the transcriptional level
through both p53-dependent and p53-independent
mechanisms that involve a variety of factors [38].
p53, in turn, trans-activates several genes involved
in growth control and the presence of two p53-
responsive elements in the promoter region of
the mouse, rat and human p21waf1/cip1 genes
suggests a role for this protein in transcription
activation after DNA damage [38]. Other stimuli
(RAS, c-Rel, Neu Diff. Factor, Zta, ribonucleotide
inhibitors) can induce p21waf1/cip1 gene expression
through up-regulation and/or stabilization of
the p53 protein [38]. Also, induction of p53-
independent p21waf1/cip1 gene transcription requires
the activation of transcription factors by different
stimuli and binding to their cognate sequences
in the promoter region. Phorbol ester (PMA) and
okadaic acid induce p21waf1/cip1 gene transcription
by stimulating Sp1 binding to the corresponding
response elements in human leukemic cell U937
[47]. Also butyrate, transforming growth factor-
b (TGF-b), lovastatin, trichostatin A, and NGF
induce p21waf1/cip1 gene transcription. Indeed,
several Sp1 binding sites are clustered within the
120 bp proximal to the transcription start site in
the p21waf1/cip1 human gene promoter; in all
cases, the role of the Sp1 site 3 resulted to be
crucial [36,48–51]. The experiments presented
here (Figure 6) clearly show that a major role in
p21waf1/cip1 induction by cladosporol A is played by
Sp1 and not by p53. Deletion of the p53 binding
sites did not affect the response, whereas deletion
or site-directed mutants of the Sp1binding sites
caused a dramatic reduction of p21waf1/cip1 reporter
gene expression (Figure 6E). Note that HT-29 cells
bear a mutated form of p53 and, in fact, we ob-
served no signiﬁcant variations in p53 expression
after cladosporol A treatment (20 mM for 4, 6, and
8 h) (Supplementary data 5). In addition, we tested
the effects of cladosporol A both in p53 þ/þ and
p53/ HCT116 cells. Despite a difference in basal
p21waf1/cip1 protein levels, the relative increase in
p21waf1/cip1 expression, which we detected in both
cells, was similar, conﬁrming that the presence of a
functional p53 is not required (Supplementary
data 6). The increase in p21waf1/cip1 expression is as-
sociated to the G1 phase arrest also in cladosporol
A-treated p53 þ/þ and p53/ HCT116 cells as
reported in Supplementary Data 7. Both cell types
are blocked in G1 phase, even if only for 12 h, and
then they start again to progress in the cell cycle,
demonstrating that the G1 arrest does not depend
on p53. The shorter cell cycle arrest observed in
both p53 þ/þ and p53/ HCT116 cells could be
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due to the different cellular context in which clado-
sporol A exerts its action.
Although we deﬁnitively demonstrated that
activation of p21waf1/cip1 gene transcription by
cladosporol A in HT-29 cells involves a p53-
independent pathway, we cannot exclude that
other mechanisms and protein factors may be in-
volved in the G1 phase arrest and inhibition of
cell proliferation observed, in addition to the gene
expression variations reported. To this aim, we
analyzed changes in the HT-29 cells proteome,
following treatment with cladosporol A and found
that the steady state of several proteins was modi-
ﬁed (Supplementary Data 3). Interestingly, among
these, some play a central role in controlling the
oxidative stress response of the cell. Speciﬁcally,
the MAPK cascades, such as ERK, JNK, and p38
pathways, are activated in response to oxidant spe-
cies accumulation after administration of chemio-
preventive agents. We provide evidence that
higher doses of cladosporol A stimulate an oxida-
tive stress via different mechanisms and induce
an adaptative response through activation of
the ERK and JNK pathways (Figure 7), resulting in
a p21waf1/cip1 increase, cyclin D1 decrease, G1
phase arrest and reduced cell proliferation. Recent
reports demonstrated that cyclin D1 expression
and p53-independent p21waf1/cip1 induction are
modulated through the MAPK pathways in various
cell lines [52,53]. Although the data obtained
by proteome analysis need to be expanded, they
indicate that other factors could, directly or indi-
rectly, be targeted by the treatment and that intri-
cate mechanisms could integrate the different
actions of cladosporol A in controlling cancer cell
proliferation.
In summary, in this work we demonstrated that
cladosporol A is responsible for a diminished CRC
cells proliferation, especially in HT-29 cells, caused
by a G1 phase arrest and determined by the simul-
taneous increase of p21waf1/cip1 and decrease of sev-
eral cell cycle regulators. The enhanced p21waf1/cip1
protein levels are generated by an intense Sp1-
dependent, p53-independent p21waf1/cip1 induc-
tion of gene transcription. The results of this work
demonstrate for the ﬁrst time that ERK (and JNK
also) might function as mediator of the clado-
sporol A-induced inhibition of HT-29 cell growth,
suggesting the existence of a regulatory circuit that
integrates cell cycle regulation and the signaling
pathways both converging towards inhibition of
cell proliferation.
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